AI Analysis | Feedback

The Teva Pharmaceuticals for complex biologic drugs, making more affordable, approved versions of blockbusters like Humira or Neulasta.

Like a specialized Amgen or AbbVie, but primarily focused on developing and selling cost-effective biosimilar versions of established blockbuster drugs, rather than the original brand-names.

AI Analysis | Feedback

• UDENYCA: A biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor, currently marketed in the United States.
• Toripalimab: A novel anti-PD-1 antibody under development for the second-line treatment of melanoma in China.
• CHS-1420: An anti-TNF product candidate, which is an adalimumab (Humira) biosimilar.
• Bevacizumab biosimilar: A biosimilar candidate to Avastin.
• Ranibizumab biosimilar: A biosimilar candidate to Lucentis.

AI Analysis | Feedback

Coherus BioSciences, Inc. (CHRS), as a biopharmaceutical company, primarily sells its products to other companies within the healthcare supply chain rather than directly to individuals. Its major customers typically include:

• Pharmaceutical Wholesalers/Distributors: These companies purchase pharmaceutical products from manufacturers like Coherus BioSciences and then distribute them to hospitals, clinics, and pharmacies. The three largest pharmaceutical wholesalers in the United States are:
  • McKesson Corporation (Symbol: MCK)
  • AmerisourceBergen Corporation (Symbol: ABC)
  • Cardinal Health, Inc. (Symbol: CAH)
• Hospitals and Integrated Delivery Networks (IDNs): Large hospital systems or integrated healthcare networks may also be direct customers, purchasing biosimilar products for administration within their facilities.
• Group Purchasing Organizations (GPOs): Coherus BioSciences would likely contract with GPOs, which represent networks of hospitals and other healthcare providers, to facilitate the purchasing of their products at negotiated rates.

AI Analysis | Feedback

• Selexis SA
• Bioeq AG
• Innovent Biologics (Suzhou) Co., Ltd. (1801.HK)
• Junshi Biosciences (1877.HK, 688180.SH)

AI Analysis | Feedback

Dennis M. Lanfear - Chairman, President & Chief Executive Officer

Denny Lanfear founded Coherus in 2010 and serves as its President and Chief Executive Officer. He is a biopharmaceutical leader with a proven track record of entrepreneurial success. Prior to Coherus, Mr. Lanfear founded and served as CEO of two other companies: Saronyx, Inc., a drug development software services company, and InteKrin Therapeutics, a biopharmaceutical company. He also held various senior leadership roles at Amgen Inc. for 13 years, including Vice President of Process Development and Vice President of Market Development, where he gained substantial operations experience and integrated over 2,500 operations and staff worldwide. Coherus secured early financial backing from venture capital firms and institutional investors, including a Series A financing round of $55 million in 2011 and attracting new investors like KKR & Co. in a Series C round by May 2014.

Bryan McMichael - Chief Financial Officer

Bryan McMichael was appointed Chief Financial Officer of Coherus, effective August 1, 2024. He joined Coherus in March 2021 and has served in roles of increasing responsibility, including Interim Chief Financial Officer, Executive Vice President, Accounting, Corporate Controller, and Principal Accounting Officer. Prior to joining Coherus, Mr. McMichael served as Assistant Controller at Gilead Sciences, Inc. from May 2016 to March 2021. He also held various roles at NetApp, Inc. and began his financial career at PricewaterhouseCoopers LLP (PwC) in the United States and Europe, where he spent approximately 10 years. Mr. McMichael is a Certified Public Accountant.

Theresa LaVallee, Ph.D. - Chief Scientific & Development Officer

Dr. Theresa LaVallee joined Coherus in 2021 and brings over 25 years of experience in drug discovery and development, with a focus on oncology and inflammation. Before Coherus, she served as Vice President, Translational Medicine and Regulatory Affairs at the Parker Institute for Cancer Immunotherapy, where she provided scientific leadership for clinical strategy in immuno-oncology therapies. Her previous executive roles include positions at Celldex Therapeutics and Kolltan Pharmaceuticals (acquired by Celldex), and she was part of the immuno-oncology team at AstraZeneca (MedImmune). Dr. LaVallee began her career at EntreMed, working on the clinical development of thalidomide.

Sameer Goregaoker - Chief Commercial Officer

Sameer Goregaoker joined Coherus in December 2024 as Chief Commercial Officer, overseeing marketing, sales, market access, and commercial operations. He has over 20 years of biopharmaceutical commercialization and research experience, with a strong focus on Oncology. Prior to Coherus, Mr. Goregaoker was Vice President, Head of Marketing and Launch Readiness at Crinetics Pharmaceuticals. He also served as Vice President, Oncology Marketing at Ipsen North America for four years and spent fourteen years at Amgen in various leadership roles, including Hematology Brand leader, Sales Leader for branded Oncology and biosimilars, and Head of Oncology Digital and Patient Innovation. Earlier in his career, he worked as a research scientist at Schering Plough.

Arvind Sood - Chief Strategy and Corporate Affairs Officer

Arvind Sood joined Coherus in November 2025 as Chief Strategy and Corporate Affairs Officer, responsible for corporate development, investor relations, and government affairs. He brings over 20 years of experience, including more than two decades at Amgen as Vice President of Investor Relations. Following Amgen, he served as President of US operations for Innate Pharma and as Chief Operating Officer for Curogen, a privately held South Korean biotechnology company. Earlier in his career, Mr. Sood held roles in investor relations, financial communications, and strategy at Aventis SA (now Sanofi) and various commercial positions in sales and marketing at The Upjohn Company (now Pfizer).

AI Analysis | Feedback

The key risks for Coherus Oncology (symbol: CHRS) primarily stem from its strategic pivot to become an innovative immuno-oncology company, having divested its biosimilar business.

1. Dependence on LOQTORZI and Immuno-Oncology Pipeline Success

   Coherus Oncology's future performance is heavily reliant on the commercial success of its flagship immuno-oncology product, LOQTORZI (toripalimab-tpzi), and the successful development and eventual commercialization of its innovative oncology pipeline candidates. Challenges such as slower-than-anticipated market adoption for LOQTORZI, or clinical trial failures, safety concerns, or regulatory setbacks for pipeline assets like casdozokitug (anti-IL-27 antibody) and CHS-114 (anti-CCR8 antibody), could significantly impact the company's revenue and growth prospects.

2. Intense Competition in the Immuno-Oncology Market

   The immuno-oncology landscape is highly competitive, featuring numerous established pharmaceutical companies and a continuous influx of new therapies. Coherus Oncology's LOQTORZI and its pipeline products face substantial competition from existing and emerging immuno-oncology treatments, including other PD-1/PD-L1 inhibitors. This intense competitive environment could lead to pricing pressures, difficulties in gaining market share, and slower revenue growth for Coherus Oncology's offerings.

3. Clinical Development and Regulatory Approval Risks

   Developing novel oncology drugs is inherently risky, involving complex and lengthy clinical trials and stringent regulatory approval processes. There is a risk that Coherus Oncology's pipeline candidates may not meet primary endpoints in clinical trials, encounter unexpected side effects, or face delays. Furthermore, obtaining regulatory approvals for new indications for LOQTORZI or for new pipeline products in the United States and other markets is critical and subject to uncertainties and potential delays from regulatory bodies like the FDA.

AI Analysis | Feedback

AI Analysis | Feedback

Coherus BioSciences, Inc. (CHRS) operates in the biosimilar and immuno-oncology markets, with several key products addressing significant therapeutic areas.

Addressable Markets for Coherus BioSciences' Main Products:

• UDENYCA (Pegfilgrastim biosimilar): The global pegfilgrastim market size was approximately USD 1,654.2 million in 2024. The U.S. market for pegfilgrastim was valued at USD 522.02 million in 2024 and is projected to grow at a CAGR of 9.5% during the forecast period. The global pegfilgrastim biosimilars market is estimated to be valued at USD 1.84 billion in 2025 and is expected to reach USD 3.39 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.1% from 2025 to 2032. North America holds the largest share of the global pegfilgrastim biosimilars market, with the U.S. accounting for over 40.5% of this share in 2025.
• Adalimumab biosimilar (biosimilar to Humira): The global Humira (adalimumab) market size was estimated at USD 10.34 billion in 2024 and is projected to decline to USD 4.11 billion by 2030 due to biosimilar competition. The U.S. Humira market generated a revenue of USD 7,379.3 million in 2024. The adalimumab biosimilar market was valued at USD 598.30 million in 2022 and is expected to reach USD 3,431.48 million by 2030, with a CAGR of 24.4% from 2023 to 2030. North America held a dominant market position for adalimumab biosimilars, capturing over 43.5% market share in 2023.
• Bevacizumab biosimilar (biosimilar to Avastin): Global sales of bevacizumab biosimilars collectively surpassed USD 2.2 billion as of 2022. The U.S. is identified as the most valuable market for bevacizumab biosimilars, holding 66% of the total market share as of 2022. The bevacizumab biosimilars market size is expected to grow from USD 1.64 billion in 2025 to USD 2.42 billion in 2030, at a CAGR of 8.2%. North America was the largest region in the bevacizumab biosimilars market in 2025, accounting for approximately 45% of the global market share.
• Ranibizumab biosimilar (biosimilar to Lucentis): The global Lucentis (ranibizumab) and biosimilar market was valued at approximately USD 7.5 billion in 2024 and is anticipated to reach around USD 17.6 billion by 2033, reflecting a CAGR of 8.8% from 2025 to 2033. North America holds the largest share of approximately 45% in this market. The ranibizumab market size is projected to grow from USD 2.76 billion in 2025 to USD 3.31 billion in 2030.
• Toripalimab (anti-PD-1 antibody): The global PD-1 and PD-L1 inhibitors market size was valued at USD 49.15 billion in 2024 and is poised to grow to USD 209.83 billion by 2033, at a CAGR of 17.5% from 2026 to 2033. The melanoma segment within this market is expected to witness the fastest CAGR of 20.2% from 2026 to 2033. North America currently dominates the global PD-1/PD-L1 inhibitors market. The global PD-1 inhibitor drugs market size is expected to increase from USD 48.69 billion in 2025 to approximately USD 179.77 billion by 2034.

AI Analysis | Feedback

Coherus BioSciences, Inc. (CHRS) is expected to drive future revenue growth over the next 2-3 years through a strategic focus on oncology, leveraging its lead product, pipeline assets, and market expansion efforts.

Here are 3-5 expected drivers of future revenue growth:

• Accelerated Growth of LOQTORZI Sales: Coherus anticipates significant growth from LOQTORZI (toripalimab), its PD-1 inhibitor for nasopharyngeal carcinoma (NPC). LOQTORZI net revenue doubled from $19.1 million in 2024 to $40.8 million in 2025, representing 113% year-over-year growth. Management projects an average quarter-over-quarter demand growth of 10% to 15% and aims for LOQTORZI sales to reach an annualized run rate of $175 million by 2028, securing approximately 70% of the estimated $250 million addressable U.S. NPC market. This growth is further supported by an expanded commercial team in 2026 and increased investment in data systems to identify patients.
• Expansion of LOQTORZI's Label and Indications: Beyond its current approval, Coherus plans to expand LOQTORZI's market by pursuing new indications and developing combination therapies with its pipeline assets and industry partners. This strategy aims to broaden the addressable patient population and extend the product's market reach.
• Advancement and Potential Commercialization of Novel Oncology Pipeline Assets: The company's pipeline includes two promising mid-stage clinical candidates: tagmokitug (a CCR8 Treg depleter) and casdozokitug (an anti-IL-27 inhibitor), acquired through the Surface Oncology acquisition. Casdozokitug has shown promising Phase 2 data in liver cancer with a 17% complete response rate. Initial clinical data readouts for these assets are expected from mid-2026 onwards, paving the way for potential future commercialization and revenue streams.
• Strategic Partnerships and Ex-U.S. Licensing Deals: Coherus is actively pursuing strategic collaborations and ex-U.S. licensing deals for its key oncology products and pipeline assets. An example includes exploring tagmokitug in combination with talquetamab in prostate cancer through a collaboration with Johnson & Johnson. These partnerships can generate upfront payments, milestone payments, and royalties, contributing to revenue growth and extending the global reach of its therapies.

AI Analysis | Feedback

Share Repurchases

• Coherus announced in April 2025 plans to repurchase approximately $170 million aggregate principal amount of its 1.500% Convertible Senior Subordinated Notes due 2026.
• Approximately $60 million aggregate principal amount of these Convertible Notes will remain outstanding after the initial repurchase.
• The company intends to repurchase the remaining $60 million in Convertible Notes following the close of the UDENYCA divestiture.

Share Issuance

• In May 2023, Coherus priced an underwritten public offering of 11,764,706 shares of its common stock at $4.25 per share.
• The company sold 4,634,995 shares of common stock and warrants for approximately $7.9 million in net proceeds in October 2025.
• In February 2026, Coherus sold 28,600,000 shares of common stock in a public offering for approximately $47.0 million in net proceeds.

Capital Expenditures

• Coherus reported capital expenditures of $1 million for the year 2025.
• Proceeds from a May 2023 share offering were intended for general corporate purposes, including the cost of manufacturing clinical and commercial supplies of product candidates and products.
• Research and development (R&D) expenses from continuing operations increased to $108.9 million in 2025, driven primarily by development costs for pipeline candidates casdozokitug and tagmokitug.